Investment analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics stock opened at $1.42 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45. The company has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53.
Nabriva Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Nabriva Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What Investors Need to Know to Beat the Market
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Basic Materials Stocks Investing
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.